MARS: Mutation-Adjusted Risk Score for Advanced Systemic Mastocytosis

2019122 citationsJournal Articlehybrid Open Access

Authors

Mohamad Jawhar · University Medical Centre Mannheim

Juliana Schwaab · University Medical Centre Mannheim

Iván Álvarez‐Twöse · Spanish Multiple Sclerosis Network

Khalid Shoumariyeh · University of Freiburg

Nicole Naumann · University Hospital Heidelberg

Johannes Lübke · Heidelberg University

Cecelia Perkins

Abstract

The MARS is a validated, five-parameter, WHO-independent prognostic score that defines three risk groups among patients with AdvSM and may improve up-front treatment stratification for these rare hematologic neoplasms.

Topics & Keywords

Mast cells and histamine Asthma and respiratory diseases Veterinary Oncology Research

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal of Clinical Oncology

Volume 37, Issue 31, pp. 2846-2856

DOI: 10.1200/jco.19.00640

Field-Weighted Citation Impact: 5.33